Opinion
The biopharmaceutical industry is facing a series of intertwined new and old challenges: vaccine hesitancy can be traced back hundreds of years, clinical trial initiation timelines are delayed by bureaucratic processes, biotech financing is highly competitive, and information overload in the AI era is pushing the industry toward incremental improvements rather than disruptive breakthroughs. Several industry executives—including Silvia Taylor of Novavax, Mayank Gandhi of NEOK Bio, Dr. Anup Sabharwal of Syneos Health, and Svetlana Lucas of Scribe Therapeutics—shared their insights on these topics.
This article reviews the core reflections of four executives from Organon, Editas Medicine, Ardelyx, and Immunocore during their first 90 days in office, revealing key challenges and coping strategies in leadership transitions.
At the 2026 BIO conference, multiple pharmaceutical leaders noted that although AI is increasingly applied in drug development, it has still not achieved the expected results in shortening R&D cycles, designing drugs from scratch, breaking through keyword limitations, implementing strategies, uncovering biological mysteries, and promoting big-picture thinking.
The U.S. Department of Health and Human Services (HHS) faced massive layoffs this week, with agencies such as the FDA and CDC severely impacted. Industry leaders and public health experts have spoken out, expressing concerns over damage to regulatory capacity, scientific research systems, and public health response capabilities.
In 2024, AI became mainstream in the pharmaceutical industry, with AlphaFold winning the Nobel Prize in Chemistry marking a new era. Looking ahead to 2025, industry leaders predict that AI will play a greater role in drug discovery, clinical trials, personalized medicine, patient safety, and other areas, while also facing challenges such as talent shortages and regulatory uncertainty.